Skip to content
Fear and GreedStocks25Crypto22
Start for free

Medpace Holdings stock

MEDPNASDAQ

Medpace Holdings, Inc., HealthcareISIN US58506Q1094

$656.84▼ $7.93 (−1.2%)Closing price of 12 Nov 2026

82Score 82 out of 100, Strong

Turn on early warning

Price and trend

81 / 100

Price history

+9.9% in one year

The chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Above the 200-day line: the price is 24% above it.

Trend change

Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.

Momentum

Normal: the price is neither overheated nor sold off (RSI 46).

Distance to the high

The price is 5.2% below its 52-week high. Largest decline in 10 years: 43% (December 2021 to April 2022).

Chart figures for advanced users
SMA 50$628.31
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$531.71
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)46
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDbelow the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$393.42
The lowest closing price of the last twelve months.
Resistance$692.68
The highest closing price of the last twelve months.
What would $1,000 in Medpace Holdings have become?Return triangle for Medpace Holdings
Market cap
$18.37B
Div. yield
no dividend
36.0
33.7
on earnings for the next twelve months ($19.50 per share)
Fair value
$551.02

Snapshot

Computed from the data by fixed rules, no AI

  • Medpace Holdings, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $18.37B, is number 14 of 37 companies in its industry on MEQIRI.
  • In fiscal 2025 it reported revenue of $2.53B (up 20% year on year) and earnings of $451.12M (up 11.6%).
  • For fiscal 2026, analysts expect on average revenue of $2.85B (up 12.6%) and adjusted earnings per share of $18.24 (up 19.2%).
Show more
  • MEQIRI Score 82 out of 100 (Strong): rank 10 of 702 in Healthcare, median 53.
  • The P/E is 36 (Medical (Diagnostics & Research) median 33.7, own median of recent years 33.8).
  • Our model puts fair value at $551.02, with the price 19% above it.

In plain words

The numbers on this page in plain words, written by an AI

Strengths

  • High return on capitalReturn on invested capital 220% in fiscal 2025, Medical (Diagnostics & Research) median 6.4%.Profitability 85
  • Earnings per share growingUp 30.9% a year since 2020.Growth 98
  • Growing faster than its industryRevenue up 22.3% a year since 2020, Medical (Diagnostics & Research) median 6.6%.Growth 98

Weaknesses

None of our weakness checks flags anything. Crash risk is measured separately.

82/ 100
MEQIRI Score
Strong

Its standout strengths are fundamentals and growth, while valuation holds the score back.

Daily figure as of 13 Nov 2026

How the score is calculated

Score overview

Score since yesterday from 83 to 82.

Fundamentals are strong, with stable profits and strong cash generation.

Profit consistency100% of years
Cash conversion (free cash flow to earnings, 12 months)129%
ROIC (12 months)75.7%
Positive free cash flow100% of years
How this category is measured

Score history

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Crash risk medium

How well MEQIRI warns

In the middle among stocks ranked 101 to 1,000.

From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.

What drives the risk

  • high growth grade (crashed more often in the backtest)

What lowers it

  • solid fundamentals
  • price near its 52-week high

Valuation

Valuation signal

Fairly valued
Price
$656.84
Fair value
$551.02
Gap to fair value
+19%

In our model the price counts as cheap below $393.59 and expensive above $918.37 (uncertainty high, based on the price swings of the past year).

The two parts of the fair value come to $487.53 (cash-flow model) and $614.52 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.

Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $513.06, at 8.1% it would be $606.72.

Valuation metrics

3.64
28.1
Fair value (model)
$551.02
Earnings part $614.52 (earnings per share $18.25 × 33.7)

Half from the cash-flow model, half from earnings times the industry P/E (33.7).

Calculate with your own assumptions

Company performance

This shows several years of history with an automatic assessment.

Revenue

13 years

In the twelve months to 30 Sep 2026, revenue rose 20.4% on the twelve months before. Revenue has grown strongly since 2013, at around 20% per year.

Margins

13 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2025: gross 30%, operating 21%, net 18%.

Debt & balance sheet

latest quarter
0.25
> 100x
0.83
Cash & equivalents
$705.32M

The balance sheet is solid, with low debt and comfortable interest coverage.

Earnings

Next earnings
8 Feb 2027in 87 days
Last reported
21 Oct 2026EPS reported $4.84 (expected $4.44)above expectations

Analyst estimates

Analysts have raised their 2026 earnings estimate by 3.6% since 15 Oct 2026.

Fiscal 202610 analysts
Earnings per share
$18.24+3.6%
Revenue
$2.85B0.0%
Fiscal 202710 analysts
Earnings per share
$19.70+1.8%
Revenue
$3.02B−0.1%

MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.

Company outlook confirmed

Share price after the results: +13.9%

Updated 2026 guidance given: revenue of $2.805 billion to $2.885 billion and EPS of $17.25 to $17.95, with no comparison to the earlier guidance.

Supporting passage from the call, verbatim
“Full year 2026 total revenue is now expected in the range of $2.805 billion to $2.885 billion representing growth of 10.9% to 14% over 2025 total revenue of $2.53 billion Our 2026 EBITDA is now expected in the range of $618 million to $642 million representing growth of 10.8% to 15.1% compared to EBITDA of $557.7 …”

The outlook is not part of the score and not a recommendation to buy or sell.

From the earnings call on 23 Jul 2026 (fiscal Q2 2026), read by AI.

Insiders

Open-market purchases and sales by executives, board members and major holders

All insider purchases

No open-market purchases in the last 6 months. 8 insiders sold, $230.23M in total.

Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.

  • Ewald Stephen PSale

    29 Oct 2026, General Counsel & Corp. Secy.

    Shares
    1,245
    Price
    $690.00
    Value
    $859,050
  • Burwig Susan ESale

    27 Oct 2026, Exec. VP, Operations

    Shares
    3,940
    Price
    $677.00
    Value
    $2.67M
  • Burwig Susan ESale

    26 Oct 2026, Exec. VP, Operations

    Shares
    16,060
    Price
    $677.00
    Value
    $10.87M
Show 32 more
  • Troendle August J.Sale

    30 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    21,966
    Price
    $625.47
    Value
    $13.74M
  • Troendle August J.Sale

    29 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    26,701
    Price
    $621.02
    Value
    $16.58M
  • Troendle August J.Sale

    28 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    2,410
    Price
    $620.07
    Value
    $1.49M
  • Troendle August J.Sale

    25 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    154
    Price
    $620.60
    Value
    $95,572
  • Troendle August J.Sale

    24 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    27,833
    Price
    $621.33
    Value
    $17.29M
  • Troendle August J.Sale

    23 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    16,083
    Price
    $628.64
    Value
    $10.11M
  • Troendle August J.Sale

    22 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    49,018
    Price
    $628.11
    Value
    $30.79M
  • Troendle August J.Sale

    21 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    21,883
    Price
    $623.29
    Value
    $13.64M
  • Troendle August J.Sale

    17 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    10,880
    Price
    $620.40
    Value
    $6.75M
  • Troendle August J.Sale

    16 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    8,770
    Price
    $621.29
    Value
    $5.45M
  • Troendle August J.Sale

    15 Sept 2026, 10 percent owner, officer: President & CEO

    Shares
    15,971
    Price
    $620.84
    Value
    $9.92M
  • Troendle August J.Sale

    27 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    650
    Price
    $620.27
    Value
    $403,176
  • Kraft Robert O.Sale

    26 Aug 2026, Board

    Shares
    3,858
    Price
    $617.81
    Value
    $2.38M
  • Troendle August J.Sale

    26 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    4,000
    Price
    $620.03
    Value
    $2.48M
  • Troendle August J.Sale

    25 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    673
    Price
    $620.38
    Value
    $417,516
  • Troendle August J.Sale

    24 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    1,983
    Price
    $620.23
    Value
    $1.23M
  • Troendle August J.Sale

    21 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    13,995
    Price
    $624.45
    Value
    $8.74M
  • Brady Kevin M.Sale

    20 Aug 2026, CFO & Treasurer

    Shares
    3,400
    Price
    $625.24
    Value
    $2.13M
  • Troendle August J.Sale

    20 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    27,174
    Price
    $618.79
    Value
    $16.81M
  • Troendle August J.Sale

    19 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    15,609
    Price
    $606.47
    Value
    $9.47M
  • Carley Brian TSale

    19 Aug 2026, Board

    Shares
    5,000
    Price
    $608.63
    Value
    $3.04M
  • Davenport Fred B JrSale

    19 Aug 2026, Board

    Shares
    7,283
    Price
    $606.15
    Value
    $4.41M
  • Troendle August J.Sale

    13 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    458
    Price
    $600.39
    Value
    $274,979
  • Troendle August J.Sale

    12 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    11,366
    Price
    $601.53
    Value
    $6.84M
  • McCarthy Cornelius P. IIISale

    11 Aug 2026, Board

    Shares
    1,140
    Price
    $605.37
    Value
    $690,122
  • Troendle August J.Sale

    11 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    17,610
    Price
    $605.11
    Value
    $10.66M
  • Troendle August J.Sale

    10 Aug 2026, 10 percent owner, officer: President & CEO

    Shares
    5,534
    Price
    $601.53
    Value
    $3.33M
  • McCarthy Cornelius P. IIISale

    7 Aug 2026, Board

    Shares
    795
    Price
    $585.07
    Value
    $465,131
  • Troendle August J.Sale

    28 Jul 2026, 10 percent owner, officer: President & CEO

    Shares
    3,510
    Price
    $600.01
    Value
    $2.11M
  • Burwig Susan ESale

    28 Jul 2026, Exec. VP, Operations

    Shares
    7,500
    Price
    $600.00
    Value
    $4.5M
  • Troendle August J.Sale

    27 Jul 2026, 10 percent owner, officer: President & CEO

    Shares
    3,728
    Price
    $600.85
    Value
    $2.24M
  • Ewald Stephen PSale

    28 May 2026, General Counsel & Corp. Secy.

    Shares
    16,349
    Price
    $450.00
    Value
    $7.36M

Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.

What happened at Medpace Holdings

The key events of the last six months from our own data. A click takes you to the matching card.

Sector comparison

702 rated companies in Healthcare

Rank 10 of 702
10/ 702
This company
82
Sector median
53

Categories against the sector median

ProfitabilityMedian of 702 companies85 (median 38)47 above the median
GrowthMedian of 702 companies98 (median 54)44 above the median
FundamentalsMedian of 702 companies100 (median 46)54 above the median
ValuationMedian of 471 companies with a value33 (median 55)22 below the median
StabilityMedian of 702 companies64 (median 67)3 below the median
Capital allocationMedian of 702 companies89 (median 39)50 above the median
Technical analysisMedian of 702 companies81 (median 69)12 above the median
MomentumMedian of 702 companies77 (median 70)7 above the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Medical (Diagnostics & Research)

The next larger and next smaller companies by market value

All 37 Medical (Diagnostics & Research) stocks

ETFs that hold Medpace Holdings

Held by 17 ETFs on Xetra. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
L&G Healthcare Technology & Innovation UCITS ETFXMLH1.97%0.49%€318.64M
iShares Healthcare Innovation UCITS ETF2B781.47%0.40%€1.5B
iShares Nasdaq US Biotechnology UCITS ETF2B701.16%0.35%€1.25B
Show 5 more
Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ0.94%0.25%€45.16M
First Trust US Large Cap Core AlphaDEX UCITS ETFFTGU0.45%0.75%€142.73M
State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY40.43%0.30%€5.36B
iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG0.24%0.43%€2.5B
State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS0.15%0.45%€1.54B

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data status and sources

Score
Daily value of 13 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Original filings at the SECReport a data error

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Strong, published since 7 Nov 2026 (in the score history since 31 May 2022)
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
Full disclosures, methodology and data sourcesAll ratings of the last 12 monthsHow the score is calculated

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy